Cell-Based Microarrays

A special issue of BioTech (ISSN 2673-6284).

Deadline for manuscript submissions: closed (31 March 2016) | Viewed by 203

Special Issue Information

Dear Colleagues,

In 2001, Ziauddin and Sabatini introduced the first cell-based microarray as a microarray-driven gene expression system. In the original set-up, different cDNA vectors were printed on a glass support. After, cells were grown over the whole surface, thus resulting in a cellular response in the printed locations. Subsequent publications have matched the technique to diverse applications involving RNAi and compounds. The potential of this method for performing gene function analysis and for identifying novel therapeutic targets and agents has now been clearly shown. Thus, cell-based microarrays have become an appreciated tool in basic research and drug discovery.

The advancement of miniaturized cell-based microarrays offers a multitude of advantages that are out of reach for conventional macroscale cell screening methods, which use microtiter plates. Amongst other advantages, the small dimensions of typical cell-based microarrays greatly reduce consumables, cell and drug consumption; this advantage is particularly important for rare cell analysis and cost reductions.

In this Special Issue, we invite material regarding new developments, technological advancements, and applications involving cell-based microarrays. Information about the new developments associated with data analysis and data mining is also critical in the area of cell-based microarrays.

Dr. Holger Erfle
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell-based microarrays
  • reverse transfection
  • screening
  • gene perturbation
  • data analysis
  • cell types
  • cellular assays

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop